Magenta Nabs More Cash, Licenses Drug To Boost Transplant Pipeline – Xconomy

By NEVAGiles23

Xconomy Boston

Magenta Therapeutics said today it has doubled its money with a $50 million Series B round led by GV, formerly Google Ventures. The Cambridge, MA-based startup spun out of Harvard University last year with nearly $50 million in launch money to develop improved bone marrow transplants.

Magenta has also licensed a drug from Novartis that it says could help boost the number of healthy stem cells that are delivered into a patients body, a key procedure in a transplant.

Used to treat people with cancer and other blood-borne diseases, a bone marrow transplant starts with a procedure to kill a patients diseased blood stem cells, which live in the bone marrow. The diseased cells are then replaced with healthy stem cells, usually from a donor. Though growing safer, its still a risky process, especially for elderly or frail patients. Deaths related to the treatment have dropped below 20 percent in recent years, but Magentas founders as well as researchers at Stanford University are among the groups working to improve the complicated steps.

Magenta is developing three types of drugs, each for a different procedure in the transplant process. It will test them as separate products but try to market them as a suite to transplant clinics, according to management.

The drug Magenta licensed from Novartis is applied to cells from donated umbilical cord blood, which have different properties than cells from blood donated by adults. The drug, which recently completed an early stage study, is meant to stimulate the blood cells to replicate faster outside the body, providing a bigger population to put back into the patient. The more cells, the better the chance that the new healthy cells will engraft, or survive in the patients bone marrow.

Magenta also aims to develop an alternative to chemotherapy or radiation, which a patient receives before a transplant to kill his or her diseased stem cells; and a treatment to coax an adult donors stem cells out of the bone marrow and into the bloodstream, where the cells are easier to harvest for the transplant.

Other investors in the new round are previous backers Third Rock Ventures, Atlas Venture, Partners Innovation Fund, and Access Industries, and new investors including Casdin Capital and BeTheMatch BioTherapies, which is affiliated with the nonprofit international bone marrow registry NMDP/Be The Match.

Magenta said it would work with BeTheMatch BioTherapies on research and development.

Photo Bone Marrow Donation by Andrew Ratto via a Creative Commons 2.0 license.

Alex Lash is Xconomy's National Biotech Editor. He is based in San Francisco.

Read this article:
Magenta Nabs More Cash, Licenses Drug To Boost Transplant Pipeline - Xconomy

Related Post


categoriaBone Marrow Stem Cells commentoComments Off on Magenta Nabs More Cash, Licenses Drug To Boost Transplant Pipeline – Xconomy | dataMay 2nd, 2017

About...

This author published 858 posts in this site.
Just for fun

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024